AbstractObjective To explore the regulatory effect of glutathione S-transferase P1(GSTP1) on the radiosensitivity of mouse Lewis lung cancer (LLC) cells. Methods GSTP1-shRNA lentivirus and negative control lentivirus were used to respectively infect the LLC cells, and stable transgenic strains were selected. Real-time PCR and Western blot were conducted to quantitatively measure the expression levels of GSTP1 mRNA and protein in the LLC cells to verify the knockdown effect. The cell counting kit-8(CCK-8) assay was used to detect cell viability after irradiation. The colony formation assay was utilized to assess the cell proliferation ability after irradiation. Flow cytometry was performed to assess the level of cell apoptosis after irradiation. The tumor-bearing mice were established and irradiated to detect the changes in the tumor volume after irradiation. TUNEL staining was employed to detect the level of tumor apoptosis after irradiation. Immunofluorescence was used to detect the number of CD+4CD+8 T cells in the tumor after irradiation. Results Real-time PCR and Western blot showed that after shRNA lentivirus interference, the expression levels of GSTP1 mRNA and protein were significantly down-regulated. Down-regulation of GSTP1 reduced cell viability and proliferation, and increased the rate of cell apoptosis after irradiation. The tumor volume of the tumor-bearing mice after irradiation in the GSTP1 knockdown group was significantly smaller than that in the NC group, whereas the tumor apoptosis rate was significantly higher and the number of infiltrating CD+4CD+8 T cells in the tumor was remarkably higher compared with those in the control group. Conclusion Knockdown of GSTP1 can significantly increase the radiosensitivity of LLC cells and enhance the infiltration of lymphocytes in tumor tissues.
Fund:Health Care Project of the Health Bureau of the Military Commission Logistics Support Department (20BJZ40);Open Project of National Geriatric Disease Clinical Medicine Research Center(ZXD2004)
Liang Yanjie,Zhang Pei,Du Lehui et al. Regulation of glutathione S-transferase P1 on the radiosensitivity of mouse Lewis lung cancer cells[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 498-502.
Liang Yanjie,Zhang Pei,Du Lehui et al. Regulation of glutathione S-transferase P1 on the radiosensitivity of mouse Lewis lung cancer cells[J]. Chinese Journal of Radiation Oncology, 2021, 30(5): 498-502.
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108. DOI:10.3322/caac.21262. [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338. [3] Yuan M, Huang LL, Chen JH, et al. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer[J]. Signal Transduct Target Ther, 2019, 4:61. DOI:10.1038/s41392-019-0099-9. [4] Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update[J]. Cancer Epidemiol Biomarkers Prev, 2016, 25(1):16-27. DOI:10.1158/1055-9965. EPI-15-0578. [5] Raghav KP, Gonzalez-Angulo AM, Blumenschein GR Jr. Role of HGF/MET axis in resistance of lung cancer to contemporary management[J]. Transl Lung Cancer Res, 2012, 1(3):179-193. DOI:10.3978/j.issn.2218-6751.2012.09.04. [6] Awasthi YC, Ramana KV, Chaudhary P, et al. Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity[J]. Free Radic Biol Med, 2017, 111:235-243. DOI:10.1016/j.freeradbiomed.2016.10.493. [7] Fujikawa Y, Nampo T, Mori M, et al. Fluorescein diacetate (FDA) and its analogue as substrates for Pi-class glutathione S-transferase (GSTP1) and their biological application[J]. Talanta, 2018, 179:845-852. DOI:10.1016/j.talanta.2017.12.010. [8] Zhang X, Zhu J, Xing R, et al. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1[J]. Lung Cancer, 2012, 77(3):488-494. DOI:10.1016/j.lungcan.2012.05.107. [9] Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(1):212-224. DOI:10.1016/j.ijrobp.2020.05.002. [10] Chatterjee A, Gupta S. The multifaceted role of glutathione S-transferases in cancer[J]. Cancer Lett, 2018, 433:33-42. DOI:10.1016/j.canlet.2018.06.028. [11] Cui J, Li G, Yin J, et al. GSTP1 and cancer:Expression, methylation, polymorphisms and signaling (Review)[J]. Int J Oncol, 2020, 56(4):867-878. DOI:10.3892/ijo.2020.4979. [12] Zhang J, Wu Y, Hu X, et al. GSTT1, GSTP1, and GSTM1 genetic variants are associated with survival in previously untreated metastatic breast cancer[J]. Oncotarget, 2017, 8(62):105905-105914. DOI:10.18632/oncotarget.22450. [13] Cowell IG, Dixon KH, Pemble SE, et al. The structure of the human glutathione S-transferase pi gene[J]. Biochem J, 1988, 255(1):79-83. DOI:10.1042/bj2550079. [14] Ali-Osman F, Akande O, Antoun G, et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins[J]. J Biol Chem, 1997, 272(15):10004-10012. DOI:10.1074/jbc.272.15.10004. [15] Katiyar T, Yadav V, Maurya SS, et al. Interaction of glutathione-s-transferase genotypes with environmental risk factors in determining susceptibility to head and neck cancer and treatment response and survival outcome[J]. Environ Mol Mutagen, 2020, 61(5):574-584. DOI:10.1002/em.22362. [16] Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression[J]. Cancer Res, 2019, 79(18):4557-4566. DOI:10.1158/0008-5472. CAN-18-3962. [17] Weichselbaum RR, Liang H, Deng L, et al. Radiotherapy and immunotherapy:a beneficial liaison?[J]. Nat Rev Clin Oncol, 2017, 14(6):365-379. DOI:10.1038/nrclinonc.2016.211. [18] Ngwa W, Irabor OC, Schoenfeld JD, et al. Using immunotherapy to boost the abscopal effect[J]. Nat Rev Cancer, 2018, 18(5):313-322. DOI:10.1038/nrc.2018.6. [19] Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J]. CA Cancer J Clin, 2017, 67(1):65-85. DOI:10.3322/caac.21358. [20] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017, 8:15618. DOI:10.1038/ncomms15618.
2021, Vol. 30 
